La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Lyell Immunopharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Lyell Immunopharma..

Lyell Immunopharma (NASDAQ:LYEL) Azioni, Catena delle Opzioni

Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Lyell Immunopharma Inc

UBS analyst Douglas Harter maintains Starwood Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) with a Neutral and raises the price target from $19.5 to $20.

News

Price Target

Analyst Ratings

STWD

UBS Maintains Neutral on Starwood Prop Trust, Raises Price Target to $20

Oppenheimer analyst Jeff Jones reiterates Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) with a Outperform and lowers the price target from $13 to $11.

Reiteration

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Oppenheimer Reiterates Outperform on Chemomab Therapeutics, Lowers Price Target to $11

Interest in blockchain technology from large institutions like BlackRock and PayPal continues to grow, setting the stage for what may be a transformative shift in finance. 
In a recent interview ahead of the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event, Sandra Ro, CEO of the Global Blockchain Business Council, offered her perspective on the factors fueling this interest and how they might influence the cryptocurrency landscape.
<h1 class="wp-block-heading">Tokenization: A New Path for Traditional Finance</h1>
According to Ro, while some institutions might engage with blockchain due to "FOMO," others are exploring its potential for creating new revenue streams through tokenizing real-world assets. 
Tokenized assets, including collateral, money market funds, and repos, offer a path to fractional ownership and direct digital transfer of ownership rights without physically moving items like gold. As Ro put it, these assets "improve capital efficiency, liquidity, and reduce frictions and potentially costs," allowing institutions to simplify asset management and transactions.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13232153/905735A6-57D3-4874-9AA1-75D037842DB3-1-10.gif" alt="" class="wp-image-646802" /></figure>
<h1 class="wp-block-heading">Rethinking Financial Products</h1>
Ro noted that despite the attention drawn by recent Bitcoin and Ethereum ETFs, she views them as merely repackaged versions of existing financial instruments. Having previously worked on regulated Bitcoin products, she commented that "they are NOT new innovations," describing both ETFs and futures as inherently traditional structures. 
Ro suggested that the fundamental transformation may occur when decentralized finance (DeFi) and centralized finance (CeFi) collaborate to create "scalable, hyper-customizable financial products with embedded cash/payment leg."
<h1 class="wp-block-heading">A Future on the Blockchain</h1>
Ro envisions financial products being issued, transacted and settled entirely on blockchain, creating a streamlined financial environment. She noted that integrating DeFi with CeFi could enable a more efficient model where all transactions occur seamlessly on-chain. Ro expressed optimism about a "world of financial innovation" still waiting to emerge as blockchain redefines managing and moving assets.
With the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event approaching, discussions will likely dive further into blockchain's role in traditional finance, especially as tokenization gains traction and reshapes possibilities for financial products. Ro's views indicate that blockchain may still have much to offer as it progresses beyond its current applications to enable flexible and customized solutions for the finance world.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. <a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a> event in New York City on Nov. 19 will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Events

Exclusives

Interview

A New Era? How Tokenization Could 'Reduce Frictions And Potentially Costs' In Finance

TotalEnergies SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) along with BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>), Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>), and Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) pledged a $500 million joint <a target="_blank" href="https://totalenergies.com/news/press-releases/cop29-totalenergies-bp-equinor-and-shell-join-forces-help-increase-access" rel="noreferrer noopener">investment </a>to support UN Sustainable Development Goal 7 (UN SDG7).
The companies jointly decided to invest in projects addressing energy access challenges, focusing on underserved communities in Sub-Saharan Africa, South, and Southeast Asia.
The initiative will support solutions such as solar home systems, mini-grids, clean cooking technologies, and enabling innovations like e-mobility and energy storage.
The investment also seeks to generate co-benefits, including job creation and improved health outcomes.
Patrick Pouyanné, Chairman and CEO of TotalEnergies,&nbsp;said, &#8220;Furthermore, we are committed to investing 400 million dollars in Liquefied Petroleum Gas facilities to develop clean cooking solutions in Africa and India, which will help 100 million people access healthier, more sustainable and, more reliable energy.&#8221;
&#8221;With this new joint initiative with our peers, we are activating another lever to contribute to high-impact local projects to help achieve the United Nations Sustainable Development Goal 7 by 2030."
This month, TotalEnergies signed a 15-year agreement with Sinopec to supply 2 million tons of <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41720697/totalenergies-bolsters-lng-presence-in-china-with-15-year-supply-deal-details" rel="noreferrer noopener">LNG annually, starting in 2028</a>.
Investors can gain exposure to the stock via&nbsp;First Trust Exchange-Traded Fund IV FT Energy Income Partners Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIPX#NYSE">EIPX</a>) and&nbsp;Octane All-Cap Value Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTA#NASDAQ">OCTA</a>).
Price Action: TTE shares are up 0.79% at $60.95 at the last check Friday.
Image via Pixabay
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42004380" target="_blank" rel="noreferrer noopener">Hyundai Gears Up For Trump&#8217;s Return To White House: Elevates US Chief Jose Munoz To Co-CEO, Appoints Former US Diplomat To Manage External Affairs</a></li>
</ul>

Equities

Large Cap

First Trust Exchange-Traded Fund IV FT Energy Income Partners Strategy ETF

EIPX

EQNR

OCTA

SHEL

TotalEnergies Joins BP, Equinor, And Shell In $500M Drive For Global Energy Access

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and lowers the price target from $190 to $180.

ASND

Oppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $180

RBC Capital analyst Maurice Choy maintains Atco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACO#TSX">ACO</a>) with a Sector Perform and raises the price target from C$50 to C$51.

TSX:ACO

TSX:ACO/X

RBC Capital Maintains Sector Perform on Atco, Raises Price Target to C$51

UBS analyst Brian Reynolds maintains ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) with a Buy and raises the price target from $112 to $132.

UBS Maintains Buy on ONEOK, Raises Price Target to $132

GORV

Lazydays Holdings Agreed To Exchange All Outstanding Convertible Preferred Stock For Common Stock At $1.03 Per Share

<a href="https://www.clinicaltrials.gov/study/NCT04994483?cond=Alzheimer%20Disease&amp;term=simufilam&amp;rank=3" title="https://www.clinicaltrials.gov/study/NCT04994483?cond=Alzheimer%20Disease&amp;term=simufilam&amp;rank=3">https://www.clinicaltrials.gov/study/NCT04994483?cond=Alzheimer%20Disease&amp;term=simufilam&amp;rank=3</a>

Biotech

Trading Ideas

General

SAVA

Cassava Sciences' Simufilam 100 Mg For Mild-To-Moderate Alzheimer's Disease (RETHINK-ALZ) Posted On ClinicalTrials Website On November 15, 2024

UBS analyst Brian Reynolds maintains MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) with a Buy and raises the price target from $51 to $55.

MPLX

UBS Maintains Buy on MPLX, Raises Price Target to $55

Stifel analyst Drew Crum maintains OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) with a Buy and lowers the price target from $34 to $31.

ONEW

Stifel Maintains Buy on OneWater Marine, Lowers Price Target to $31

UBS analyst Shneur Gershuni maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Buy and raises the price target from $232 to $265.

UBS Maintains Buy on Cheniere Energy, Raises Price Target to $265

Last month, U.S. District Judge Jesse Furman of the U.S. District Court for the Southern District of New York dismissed a $6.4 billion lawsuit against issuer Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
The plaintiff, UMB Bank, had not been properly <a href="https://www.milbank.com/a/web/r333FErFizuVNYcVKYmE5F/law360-bristol-myers-win-offers-lessons-for-debt-security-holders.pdf" target="_blank" rel="noreferrer noopener">appointed</a> as the trustee for the securities and therefore lacked standing to sue on behalf of the directing holders.
The issue undermined the lawsuit, filed 17 months after Bristol Myers acquired Celgene for $80.3 billion in 2019.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41913107/bristol-myers-squibbs-14-billion-potential-analyst-upgrades-stock" rel="noreferrer noopener">Bristol-Myers Squibb&#8217;s $14 Billion Potential &#8211; Analyst Upgrades Stock</a>
UMB Bank NA filed suit against Bristol-Myers in 2021. The firm alleges that the company intentionally slow-rolled the approval process for a cancer drug to dodge paying $6.4 billion owed to former Celgene shareholders under a contingent value rights agreement.
On Thursday, Bristol Myers Squibb was again hit with a $6.7 billion lawsuit. The company allegedly delayed federal approval for three drugs to avoid paying former Celgene shareholders.
The case, filed by UMB Bank, claims the delay cost &#8220;contingent value rights&#8221; (CVR) holders an extra $9 per share in cash. The drugs involved include the cancer treatment Breyanzi.
In the third quarter of 2024, Breyanzi generated sales of $224 million, up from <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">$92 million a year ago</a>.
Per Reuters, UMB resolved the appointment issue. The bank is now confirmed as trustee, allowing it to proceed with the lawsuit. The estimated liability has increased from $6.4 billion to $6.7 billion.
Price Action: BMY stock is down 0.19% at $58.39 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42008174/fda-to-revisit-regeneron-sanofis-dupixent-for-rare-skin-disease" target="_blank" rel="noreferrer noopener">FDA To Revisit Regeneron/Sanofi&#8217;s Dupixent For Rare Skin Disease</a></li>
</ul>
Image: Shutterstock

Health Care

Legal

Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue

Camping World To Acquire Seven Dealerships From Lazydays, Adding Nearly $200M In TTM Revenue; Transaction Valued Around Book Value With $10M-$20M Net Cash Outlay And Conversion To 9.7M Lazydays Shares

Stifel analyst Jeffrey Stantial maintains Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) with a Buy and raises the price target from $13 to $14.

GAMB

Stifel Maintains Buy on Gambling.com Gr, Raises Price Target to $14

RBC Capital analyst Arthur Nagorny maintains SNC-Lavalin Gr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATRL#TSX">ATRL</a>) with a Outperform and raises the price target from C$70 to C$84.

TSX:ATRL

RBC Capital Maintains Outperform on SNC-Lavalin Gr, Raises Price Target to C$84

UBS analyst Manav Gupta maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Buy and raises the price target from $30 to $33.

UBS Maintains Buy on Kinder Morgan, Raises Price Target to $33

Investors with significant funds have taken a bearish position in Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in MPWR usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 10 options transactions for Monolithic Power Systems. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 0% being bullish and 60% bearish. Of all the options we discovered, 9 are puts, valued at $553,035, and there was a single call, worth $46,580.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $470.0 and $800.0 for Monolithic Power Systems, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Monolithic Power Systems's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Monolithic Power Systems's significant trades, within a strike price range of $470.0 to $800.0, over the past month.
<h3>Monolithic Power Systems Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731685581_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$218.3</td>
<td>$209.1</td>
<td>$213.02</td>
<td>$800.00</td>
<td>$127.8K</td>
<td align="right">103</td>
<td align="right">15</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$166.0</td>
<td>$156.0</td>
<td>$163.67</td>
<td>$750.00</td>
<td>$81.8K</td>
<td align="right">14</td>
<td align="right">5</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$117.5</td>
<td>$109.0</td>
<td>$117.5</td>
<td>$700.00</td>
<td>$58.7K</td>
<td align="right">25</td>
<td align="right">10</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$116.0</td>
<td>$111.1</td>
<td>$116.0</td>
<td>$700.00</td>
<td>$58.0K</td>
<td align="right">25</td>
<td align="right">15</td>
</tr>
<tr>
<td>MPWR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$117.5</td>
<td>$107.5</td>
<td>$115.0</td>
<td>$700.00</td>
<td>$57.5K</td>
<td align="right">25</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Monolithic Power Systems</h3>
Monolithic Power Systems is an analog and mixed-signal chipmaker, specializing in power management solutions. The firm's mission is to reduce total energy consumption in end systems, and it serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.
<h3>Current Position of Monolithic Power Systems</h3>
<ul>
<li>Currently trading with a volume of 386,024, the MPWR's price is up by 0.56%, now at $580.0. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What Analysts Are Saying About Monolithic Power Systems</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $887.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Loop Capital lowers its rating to Hold with a new price target of $660. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Monolithic Power Systems, targeting a price of $950. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $950. 
&#x2A; An analyst from Oppenheimer has revised its rating downward to Outperform, adjusting the price target to $900. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Monolithic Power Systems with a target price of $975. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Monolithic Power Systems, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

MPWR

Decoding Monolithic Power Systems's Options Activity: What's the Big Picture?

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $412,586, and 2 are calls, for a total amount of $75,090.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $82.5 to $120.0 for Novo Nordisk over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $82.5 to $120.0 over the preceding 30 days.
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731685576_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$92.50</td>
<td>$161.8K</td>
<td>653</td>
<td>693</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.66</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$90.00</td>
<td>$81.0K</td>
<td>9.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$5.05</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$105.00</td>
<td>$45.5K</td>
<td>740</td>
<td>157</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$19.15</td>
<td>$19.05</td>
<td>$19.05</td>
<td>$120.00</td>
<td>$43.8K</td>
<td>3.3K</td>
<td>42</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$92.50</td>
<td>$39.0K</td>
<td>653</td>
<td>162</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,812,025, with NVO's price down by -3.84%, positioned at $101.28.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About Novo Nordisk</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $158.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $156. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On Novo Nordisk

Investors with a lot of money to spend have taken a bullish stance on AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ASTS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for AST SpaceMobile.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 31%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $238,650, and 10 are calls, for a total amount of $2,473,300.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $50.0 for AST SpaceMobile during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AST SpaceMobile's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AST SpaceMobile's substantial trades, within a strike price spectrum from $15.0 to $50.0 over the preceding 30 days.
<h3>AST SpaceMobile Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731685571_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.0</td>
<td>$8.1</td>
<td>$8.8</td>
<td>$35.00</td>
<td>$1.7M</td>
<td>5.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$7.0</td>
<td>$6.3</td>
<td>$6.8</td>
<td>$50.00</td>
<td>$272.0K</td>
<td>4.7K</td>
<td>455</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$23.00</td>
<td>$80.0K</td>
<td>8</td>
<td>200</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.65</td>
<td>$2.45</td>
<td>$2.51</td>
<td>$25.00</td>
<td>$75.2K</td>
<td>2.0K</td>
<td>428</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$35.00</td>
<td>$72.6K</td>
<td>2.5K</td>
<td>935</td>
</tr>
</tbody>
</table>

<h3>About AST SpaceMobile</h3>
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers and finally bringing broadband to the billions who remain unconnected. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
<h3>Where Is AST SpaceMobile Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 7,710,911, with ASTS's price down by -13.02%, positioned at $23.31.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 136 days.</li>
</ul>
<h3>What Analysts Are Saying About AST SpaceMobile</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $31.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on AST SpaceMobile with a target price of $31. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AST SpaceMobile, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ASTS

Market Whales and Their Recent Bets on ASTS Options

Lyell Immunopharma (LYEL) announced that it has entered into a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotec...

Lyell to acquire ImmPACT Bio, discontinue LYL797 and LYL845 programs

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Hold rating on Lyell Immunopharma (LYEL – Research Report), with a pr...

Neutral Rating for Lyell Immunopharma Amid Strategic Shifts and Competitive Challenges

BofA analyst Geoff Meacham downgraded Lyell Immunopharma (LYEL) to Underperform from Buy with a price target of $1, down from $6. Published first o...

Lyell Immunopharma downgraded to Underperform from Buy at BofA

Lyell cut to underperform by BofA, pipeline reorganization cited

Lyell Immunopharma ( ($LYEL) ) has issued an announcement. Lyell Immunopharma, a leader in next-generation CAR T-cell therapies, has acquired ImmPA...

Lyell Immunopharma's Strategic Moves and Leadership Expansion

Warning: LYEL is at high risk of performing badly

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during...

Buy/Sell: Wall Street's top 10 stock calls this week

Lyell Immunopharma, Inc. ( ($LYEL) ) has released its Q3 earnings. Here is a breakdown of the information Lyell Immunopharma, Inc. presented to its...

Lyell Immunopharma Reports Q3 2024 Financial Results

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Hold rating on Lyell Immunopharma (LYEL – Research Report). The associated price t...

Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges

AMZN

BANC

COIN

FIBK

FSLR

GOOG

GOOGL

LYEL

WING

Press Releases

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Earnings

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Lyell Immunopharma Announces Participation in September Investor Conferences

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Comments

Lyell Immunopharma

Lyell Immunopharma (LYEL) Opzioni

Lyell Immunopharma (NASDAQ:LYEL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO